Undervalued Large-Cap Stocks on NAS August 2025

August 01, 2025

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Large-Cap

Large-Cap stocks have a market capitalization of $10 billion or more.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued stocks on the NAS

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
SRPT Sarepta Therapeutics 37.60 76.50 103.46 5730379 3661 0.00 0.0
ACHC Acadia Healthcare Co 22.61 44.00 94.60 2381117 2081 0.00 11.1
HTZ Hertz Global Holdings 6.55 11.91 81.90 11734970 2011 0.00 0.0
KC Kingsoft Cloud Holdings 11.17 19.32 72.95 1986471 2776 0.00 0.0
REGN Regeneron Pharmaceuticals 490.28 828.09 68.90 1478973 54519 0.36 12.5
CZR Caesars Entertainment 26.88 44.00 63.71 4663008 5699 0.00 0.0
SNDK SanDisk 37.69 60.64 60.89 2367139 5465 0.00 0.0
BMRN Biomarin Pharmaceutical 58.07 92.00 58.43 2180190 11409 0.00 21.5
SATS EchoStar 17.73 28.00 57.97 3481984 5078 0.00 0.0
OTEX Open Text 28.32 43.25 52.70 1325391 7473 3.66 11.6
All data provided as at market close May 29, 2025.

Company Details

Sarepta Therapeutics

SRPT:NAS

Close Price

37.60

Our Valuation

76.50

% Difference

103.46

Market Cap ($M)

3661

P/E Ratio

0.0

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates.

Access the stockcalc valuation


Acadia Healthcare Co

ACHC:NAS

Close Price

22.61

Our Valuation

44.00

% Difference

94.60

Market Cap ($M)

2081

P/E Ratio

11.1

Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.

Access the stockcalc valuation


Hertz Global Holdings

HTZ:NAS

Close Price

6.55

Our Valuation

11.91

% Difference

81.90

Market Cap ($M)

2011

P/E Ratio

0.0

Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through Hertz, Dollar and Thrifty brands. The Company has identified two reportable segments: Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean; International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean.

Access the stockcalc valuation


Kingsoft Cloud Holdings

KC:NAS

Close Price

11.17

Our Valuation

19.32

% Difference

72.95

Market Cap ($M)

2776

P/E Ratio

0.0

Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Regeneron Pharmaceuticals

REGN:NAS

Close Price

490.28

Our Valuation

828.09

% Difference

68.90

Market Cap ($M)

54519

P/E Ratio

12.5

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis.

Access the stockcalc valuation


Caesars Entertainment

CZR:NAS

Close Price

26.88

Our Valuation

44.00

% Difference

63.71

Market Cap ($M)

5699

P/E Ratio

0.0

Caesars Entertainment includes about 50 domestic gaming properties across the Las Vegas (49% of 2024 EBITDAR before corporate expenses) and regional (46%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2024.

Access the stockcalc valuation


SanDisk

SNDK:NAS

Close Price

37.69

Our Valuation

60.64

% Difference

60.89

Market Cap ($M)

5465

P/E Ratio

0.0

SanDisk Corp designs, develops and manufactures data storage solutions using flash memory, proprietary controller and firmware technologies.

Access the stockcalc valuation


Biomarin Pharmaceutical

BMRN:NAS

Close Price

58.07

Our Valuation

92.00

% Difference

58.43

Market Cap ($M)

11409

P/E Ratio

21.5

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis.

Access the stockcalc valuation


EchoStar

SATS:NAS

Close Price

17.73

Our Valuation

28.00

% Difference

57.97

Market Cap ($M)

5078

P/E Ratio

0.0

Satellite television provides the bulk of EchoStar's revenue. The firm serves about 6 million US satellite customers, about 10% of the traditional television market. It launched an internet-based television offering under the Sling brand in 2015 and serves about 2 million customers on this platform. The firm's focus is now on the wireless market. EchoStar has amassed an extensive portfolio of spectrum licenses and is building a nationwide wireless network.

Access the stockcalc valuation


Open Text

OTEX:NAS

Close Price

28.32

Our Valuation

43.25

% Difference

52.70

Market Cap ($M)

7473

P/E Ratio

11.6

Open Text Corp is engaged in the design, development, marketing, and sale of Information Management software and solutions. Its software allows clients to archive, aggregate, retrieve, and search unstructured information (such as documents, e-mail, and presentations). Its platform and services provide secure and scalable solutions for enterprises, SMBs, governments, and consumers around the world.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Sarepta Therapeutics and Acadia Healthcare are the most undervalued Large-Cap stocks on the NAS. See which other companies made the list here: https://www.stockcalc.com/Blog/undervalued-large-cap-stocks-nas-august-2025
Sarepta Therapeutics $SRPT and Acadia Healthcare $ACHC are the most undervalued Large-Cap stocks on the #NAS. See the full list here: https://www.stockcalc.com/Blog/undervalued-large-cap-stocks-nas-august-2025
Sarepta Therapeutics and Acadia Healthcare are the most undervalued Large-Cap stocks on the NAS. See which other companies made the list here: https://www.stockcalc.com/Blog/undervalued-large-cap-stocks-nas-august-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.